Search Results - "MCGOON, Michael D"

An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry by Benza, Raymond L., MD, Miller, Dave P., MS, Barst, Robyn J., MD, FCCP, Badesch, David B., MD, FCCP, Frost, Adaani E., MD, FCCP, McGoon, Michael D., MD, FCCP

“…Background The Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL Registry) was established to characterize…”
Get full text

Five-Year Outcomes of Patients Enrolled in the REVEAL Registry by Farber, Harrison W., MD, FCCP, Miller, Dave P., MS, Poms, Abby D., BS, RRT, Badesch, David B., MD, FCCP, Frost, Adaani E., MD, Rouzic, Erwan Muros-Le, MPH, Romero, Alain J., PharmD, PhD, Benton, Wade W., PharmD, Elliott, C. Gregory, MD, McGoon, Michael D., MD, FCCP, Benza, Raymond L., MD

“…BACKGROUND Pulmonary arterial hypertension (PAH) is a rare, severe disease characterized by worsening right-sided heart failure, decreasing functional status,…”
Get full text

The importance of patient perspectives in pulmonary hypertension by McGoon, Michael D, Ferrari, Pisana, Armstrong, Iain, Denis, Migdalia, Howard, Luke S, Lowe, Gabi, Mehta, Sanjay, Murakami, Noriko, Wong, Brad A

“…The assessment of objective measurement of cardiopulmonary status has helped us achieve better clinical outcomes for patients and develop new therapies through…”
Get full text

Updated Treatment Algorithm of Pulmonary Arterial Hypertension by Galiè, Nazzareno, MD, Corris, Paul A., MD, Frost, Adaani, MD, Girgis, Reda E., MD, Granton, John, MD, Jing, Zhi Cheng, MD, Klepetko, Walter, MD, McGoon, Michael D., MD, McLaughlin, Vallerie V., MD, Preston, Ioana R., MD, Rubin, Lewis J., MD, Sandoval, Julio, MD, Seeger, Werner, MD, Keogh, Anne, MD

“…The demands on a pulmonary arterial hypertension (PAH) treatment algorithm are multiple and in some ways conflicting. The treatment algorithm usually includes…”
Get full text

Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance by Farber, Harrison W., MD, Miller, Dave P., MS, McGoon, Michael D., MD, Frost, Adaani E., MD, Benton, Wade W., PharmD, Benza, Raymond L., MD

“…Background Clinical studies of pulmonary arterial hypertension have used the change in the 6-minute walk distance (6MWD) as a clinical end point; however, its…”
Get full text

The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress by Lau, Edmund M T, Tamura, Yuichi, McGoon, Michael D, Sitbon, Olivier

“…The first World Health Organization (WHO) Symposium on Pulmonary Hypertension was held in 1973 in response to the sudden increase in the number of patients…”
Get full text

The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension by Benza, Raymond L., MD, Gomberg-Maitland, Mardi, MD, FCCP, Miller, Dave P., MS, Frost, Adaani, MD, FCCP, Frantz, Robert P., MD, Foreman, Aimee J., MA, Badesch, David B., MD, FCCP, McGoon, Michael D., MD, FCCP

“…Background In pulmonary arterial hypertension (PAH), survival predictions can be important for optimization of therapeutic strategies. The present study aimed…”
Get full text

Role of Serial Quantitative Assessment of Right Ventricular Function by Strain in Pulmonary Arterial Hypertension by Hardegree, Evan L., MD, Sachdev, Arun, MD, Villarraga, Hector R., MD, Frantz, Robert P., MD, McGoon, Michael D., MD, Kushwaha, Sudhir S., MD, Hsiao, Ju-Feng, MD, McCully, Robert B., MD, Oh, Jae K., MD, Pellikka, Patricia A., MD, Kane, Garvan C., MD, PhD

“…The aim of this study was to assess whether serial quantitative assessment of right ventricular (RV) function by speckle-based strain imaging is affected by…”
Get full text

Sex Differences in the Diagnosis, Treatment, and Outcome of Patients With Pulmonary Arterial Hypertension Enrolled in the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management by Shapiro, Shelley, MD, PhD, Traiger, Glenna L., RN, MSN, Turner, Michelle, MS, McGoon, Michael D., MD, FCCP, Wason, Prieya, CCRP, Barst, Robyn J., MD, FCCP

“…Background Pulmonary arterial hypertension (PAH) is a life-threatening disease that affects more women than men. The reasons for the female preponderance are…”
Get full text

Right Ventricular Strain for Prediction of Survival in Patients With Pulmonary Arterial Hypertension by Sachdev, Arun, MD, Villarraga, Hector R., MD, Frantz, Robert P., MD, McGoon, Michael D., MD, FCCP, Hsiao, Ju-Feng, MD, Maalouf, Joseph F., MD, Ammash, Naser M., MD, McCully, Robert B., MD, Miller, Fletcher A., MD, Pellikka, Patricia A., MD, Oh, Jae K., MD, Kane, Garvan C., MD, PhD, FCCP

“…Background Pulmonary arterial hypertension (PAH) is a devastating illness of pulmonary vascular remodeling, right-sided heart failure, and limited survival…”
Get full text

Four- and Seven-Year Outcomes of Patients With Congenital Heart Disease–Associated Pulmonary Arterial Hypertension (from the REVEAL Registry) by Barst, Robyn J., MD, Ivy, D. Dunbar, MD, Foreman, Aimee J., MA, McGoon, Michael D., MD, Rosenzweig, Erika B., MD

“…Uncorrected congenital heart disease (CHD) frequently leads to pulmonary arterial hypertension (PAH), the most severe form of which is Eisenmenger syndrome…”
Get full text

Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension by Oudiz, Ronald J., MD, Galiè, Nazzareno, MD, Olschewski, Horst, MD, Torres, Fernando, MD, Frost, Adaani, MD, Ghofrani, Hossein A., MD, Badesch, David B., MD, McGoon, Michael D., MD, McLaughlin, Vallerie V., MD, Roecker, Ellen B., PhD, Harrison, Brooke C., PhD, Despain, Darrin, MS, Dufton, Christopher, PhD, Rubin, Lewis J., MD

“…Objectives This study evaluated the safety and efficacy of ambrisentan for a period of 2 years in patients with pulmonary arterial hypertension (PAH)…”
Get full text

Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis by Benza, Raymond L., MD, Miller, Dave P., MS, Foreman, Aimee J., MA, Frost, Adaani E., MD, Badesch, David B., MD, Benton, Wade W., PharmD, McGoon, Michael D., MD

“…Background Data from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) were used previously to develop a…”
Get full text

Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry by Barst, Robyn J., MD, Chung, Lorinda, MD, Zamanian, Roham T., MD, Turner, Michelle, MS, McGoon, Michael D., MD

“…Objective New York Heart Association/World Health Organization functional class (FC) is associated with outcomes in pulmonary arterial hypertension (PAH). We…”
Get full text

Portopulmonary hypertension: Results from a 10‐year screening algorithm by Krowka, Michael J., Swanson, Karen L., Frantz, Robert P., McGoon, Michael D., Wiesner, Russell H.

“…Portopulmonary hypertension (POPH) is the elevation of pulmonary artery pressure due to increased resistance to pulmonary blood flow in the setting of portal…”
Get full text

Relationship of Pulmonary Arterial Capacitance and Mortality in Idiopathic Pulmonary Arterial Hypertension by Mahapatra, Srijoy, Nishimura, Rick A., Sorajja, Paul, Cha, Stephen, McGoon, Michael D.

“…Relationship of Pulmonary Arterial Capacitance and Mortality in Idiopathic Pulmonary Arterial Hypertension Srijoy Mahapatra, Rick A. Nishimura, Paul Sorajja,…”
Get full text

Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry by Burger, Charles D, MD, Long, Pamela K, RN, Shah, Monarch R, MS, McGoon, Michael D, MD, Miller, Dave P, MS, Romero, Alain J, PharmD, PhD, Benton, Wade W, PharmD, Safford, Robert E, MD, PhD

“…BACKGROUND Hospitalization is an important outcome in pulmonary arterial hypertension (PAH), shown previously to correlate with survival. Using the Registry to…”
Get full text

Validation of two predictive models for survival in pulmonary arterial hypertension by Sitbon, Olivier, Benza, Raymond L, Badesch, David B, Barst, Robyn J, Elliott, C Gregory, Gressin, Virginie, Lemarié, Jean-Christophe, Miller, Dave P, Muros-Le Rouzic, Erwan, Simonneau, Gérald, Frost, Adaani E, Farber, Harrison W, Humbert, Marc, McGoon, Michael D

“…The French Pulmonary Hypertension Network (FPHN) registry and the Registry to Evaluate Early And Long-term Pulmonary Arterial Hypertension Disease Management…”
Get full text

Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry by Farber, Harrison W., MD, Miller, Dave P., MS, Meltzer, Leslie A., PhD, McGoon, Michael D., MD

“…Background Current guidelines recommend intravenous prostacyclin as first-line therapy for patients with pulmonary arterial hypertension (PAH) in New York…”
Get full text

Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia by Lyle, Melissa A., MD, Fenstad, Eric R., MD, McGoon, Michael D., MD, Frantz, Robert P., MD, Krowka, Michael J., MD, Kane, Garvan C., MD, PhD, Swanson, Karen L., DO

“…Background A subset of patients with hereditary hemorrhagic telangiectasia (HHT) develops pulmonary hypertension (PH) by mechanisms including pulmonary…”
Get full text